中西医结合治疗耐多药肺结核70例临床观察
参见附件(12kb)。
(衡水市第三人民医院肺科 河北 衡水053000)
【摘要】目的: 观察补金片联合3DLOZA/18DLOZ方案抗痨治疗耐多药肺结核的临床疗效。方法: 将70例耐多药肺结核患者随机分为治疗组和对照组，治疗组采用补金片联合3DLOZA/18DLOZ方案抗痨，对照组仅给予3DLOZA/18DLOZ方案抗痨。两组均给予甘草酸二胺胶囊保肝治疗。观察患者痰菌阴转率、肺CT变化、肝功损伤情况。结果: 从痰菌阴转率、肺CT变化、肝功损伤情况观察，统计资料显示，治疗组与对照组比较差异有显著性(P<0.01)。结论: 补金片联合3DLOZA/18DLOZ方案抗痨治疗耐多药肺结核时，疗效显著，可以有效减轻肝脏损伤，值得推广应用。
【关键词】补金片;3DLOZA/18DLOZ;耐多药肺结核
【Abstract】 Goal: The observation subsidy piece unites the 3DLOZA/18DLOZ plan anti-tuberculosis treatment to bear the multi-medicine pulmonary tuberculosis's clinical curative effect. Method: Bears the multi-medicine pulmonary tuberculosis patient 70 examples to divide into the treatment group and the control group stochastically, the treatment group uses the subsidy piece to unite the 3DLOZA/18DLOZ plan anti-tuberculosis, the control group only gives the 3DLOZA/18DLOZ plan anti-tuberculosis. Two groups give the glycyrrhizic acid diamidogen capsule to guarantee the liver treatment. Observes the patient phlegm fungus cloudy rate of rotation, the lung CT change, the liver function damage situation. Finally: From the phlegm fungus cloudy rate of rotation, the lung CT change, the liver function damage situation observation, the statistical data demonstrated that the treatment group and the control group comparison difference have the significance (P
【key word】Subsidy piece; 3DLOZA/18DLOZ; Bears the multi-medicine pulmonary tuberculosis
【中图分类号】R521.4 【文献标识码】A 【文章编号】1008-6455(2011)06-0405-01
耐多药结核病(multi2drugresistanttuberculosis,MDR-TB)在世界各国发生率逐年上升,其治疗至今仍是临床工作的一大难题,特别是同时耐异烟肼、利福平患者的治疗更是棘手,其特点为治愈率低,病死率高,是目前结核病控制领域急需解决的难题。我们从2007年1月-2009年12月治疗耐多药肺结核患者70例,在合理选用抗痨方案的同时,采用结合中药治疗,疗效较好,现总结报告如下 ......
(衡水市第三人民医院肺科 河北 衡水053000)
【摘要】目的: 观察补金片联合3DLOZA/18DLOZ方案抗痨治疗耐多药肺结核的临床疗效。方法: 将70例耐多药肺结核患者随机分为治疗组和对照组，治疗组采用补金片联合3DLOZA/18DLOZ方案抗痨，对照组仅给予3DLOZA/18DLOZ方案抗痨。两组均给予甘草酸二胺胶囊保肝治疗。观察患者痰菌阴转率、肺CT变化、肝功损伤情况。结果: 从痰菌阴转率、肺CT变化、肝功损伤情况观察，统计资料显示，治疗组与对照组比较差异有显著性(P<0.01)。结论: 补金片联合3DLOZA/18DLOZ方案抗痨治疗耐多药肺结核时，疗效显著，可以有效减轻肝脏损伤，值得推广应用。
【关键词】补金片;3DLOZA/18DLOZ;耐多药肺结核
【Abstract】 Goal: The observation subsidy piece unites the 3DLOZA/18DLOZ plan anti-tuberculosis treatment to bear the multi-medicine pulmonary tuberculosis's clinical curative effect. Method: Bears the multi-medicine pulmonary tuberculosis patient 70 examples to divide into the treatment group and the control group stochastically, the treatment group uses the subsidy piece to unite the 3DLOZA/18DLOZ plan anti-tuberculosis, the control group only gives the 3DLOZA/18DLOZ plan anti-tuberculosis. Two groups give the glycyrrhizic acid diamidogen capsule to guarantee the liver treatment. Observes the patient phlegm fungus cloudy rate of rotation, the lung CT change, the liver function damage situation. Finally: From the phlegm fungus cloudy rate of rotation, the lung CT change, the liver function damage situation observation, the statistical data demonstrated that the treatment group and the control group comparison difference have the significance (P
【key word】Subsidy piece; 3DLOZA/18DLOZ; Bears the multi-medicine pulmonary tuberculosis
【中图分类号】R521.4 【文献标识码】A 【文章编号】1008-6455(2011)06-0405-01
耐多药结核病(multi2drugresistanttuberculosis,MDR-TB)在世界各国发生率逐年上升,其治疗至今仍是临床工作的一大难题,特别是同时耐异烟肼、利福平患者的治疗更是棘手,其特点为治愈率低,病死率高,是目前结核病控制领域急需解决的难题。我们从2007年1月-2009年12月治疗耐多药肺结核患者70例,在合理选用抗痨方案的同时,采用结合中药治疗,疗效较好,现总结报告如下 ......
您现在查看是摘要介绍页，详见PDF附件(12kb)。